Japan
· Delayed Price · Currency is JPY OncoTherapy Science Company Description
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan.
Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage.
The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer.
In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease.
The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
| Country | Japan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Junichi Shimada |
Contact Details
Address: 1-2 Higashida-cho Kawasaki, Kagawa 210-0005 Japan | |
| Phone | 81 4 4201 6429 |
| Website | oncotherapy.co.jp |
Stock Details
| Ticker Symbol | 4564 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3202150003 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Junichi Shimada | Chief Executive Officer |